The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) by Kageaki Watanabe, MD, Yukio Hosomi, MD, PhD, Katsuhiko Naoki, MD, PhD, Yoshiro Nakahara, MD, PhD, Yoko Tsukita, MD, PhD, Hirotaka Matsumoto, MD, PhD, Kiyotaka Yoh, MD, Yasuhito Fujisaka, MD, PhD, Satoshi Takahashi, MD, PhD, Saori Takata, MD, PhD, Kazuhiro Usui, MD, PhD, Kazuma Kishi, MD, PhD, Go Naka, MD, PhD, Shu Tamano, MSS, Kohei Uemura, PhD, Hideo Kunitoh, MD, PhD

Get full text

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma by Yuji Uehara, MD, Hiroki Izumi, MD, PhD, Tetsuro Taki, MD, PhD, Tetsuya Sakai, MD, PhD, Hibiki Udagawa, MD, PhD, Eri Sugiyama, MD, PhD, Shigeki Umemura, MD, PhD, Yoshitaka Zenke, MD, PhD, Shingo Matsumoto, MD, PhD, Kiyotaka Yoh, MD, PhD, Shoko Kubota, MD, PhD, Keiju Aokage, MD, PhD, Naoya Sakamoto, MD, PhD, Shingo Sakashita, MD, PhD, Motohiro Kojima, MD, PhD, Michiko Nagamine, MD, PhD, Yukio Hosomi, MD, PhD, Masahiro Tsuboi, MD, PhD, Koichi Goto, MD, PhD, Genichiro Ishii, MD, PhD

Get full text